| · Æóðíàëû
· Êíèãè
· Î ïðîåêòå
·Ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” ïîñòóïèëè â ïðîäàæó
Èçäàòåëüñòâî “Àòìîñôåðà” èäåò â íîãó ñî âðåìåíåì è îòêðûâàåò íà ñâîåì ñàéòå ðàçäåë ýëåêòðîííûõ âåðñèé ñâîèõ êíèã. Òåïåðü âû ìîæåòå ïðèîáðåñòè íå òîëüêî òðàäèöèîííóþ áóìàæíóþ êíèãó â êàðòîííîì ïåðåïëåòå, íî è .pdf-ôàéë, ñíàáæåííûé ãèïåðññûëêàìè íà êàæäóþ ãëàâó èçäàíèÿ.  ýëåêòðîííîé âåðñèè ïðîùå îòûñêàòü ðèñóíîê è òàáëèöó. ×òîáû îáðàòèòüñÿ ê íèì, äîñòàòî÷íî íàæàòü íà ññûëêó íà êàæäûé èç íèõ. Èñ÷åçëà çàâèñèìîñòü îò òèðàæà – âû ìîæåòå ïðèîáðåñòè äàæå òå áåñòñåëëåðû, òèðàæ êîòîðûõ óæå ðàçîøåëñÿ, òàêèå êàê “Ñàðêîèäîç” èëè “Çàáîëåâàíèÿ îðãàíîâ äûõàíèÿ ïðè áåðåìåííîñòè”. Óïðîñòèëîñü ïîëó÷åíèå âàìè êíèã – â òå÷åíèå äâóõ ðàáî÷èõ äíåé ïîñëå îïëàòû òðåáóåìûå ôàéëû ïðèäóò íà âàø e-mail. Íó è íàêîíåö, öåíà – ýëåêòðîííûå âåðñèè íàøèõ êíèã ãîðàçäî äåøåâëå, ÷åì áóìàæíûå èçäàíèÿ.
Çàêàçûâàéòå ýëåêòðîííûå âåðñèè êíèã èçäàòåëüñòâà “Àòìîñôåðà” íà ñàéòå, à òàêæå ïî òåëåôîíó: (495) 730-63-51 è ïî e-mail: atm-press2012@yandex.ru
ÈÍÒÅÐÍÅÒ-ÌÀÃÀÇÈÍ
|
|
| |
Ïðàêòè÷åñêàÿ ïóëüìîíîëîãèÿ (ðàíåå – "Àòìîñôåðà. Ïóëüìîíîëîãèÿ è àëëåðãîëîãèÿ"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print) 2004 / N 1
Àíòèìèêðîáíàÿ àêòèâíîñòü ëåâîôëîêñàöèíà (Ñïèñîê ëèòåðàòóðû) Ñ.Ä. Ìèòðîõèí
Ïðîäîëæåíèå ñïèñêà ëèòåðàòóðû.
16. Sahm D. F. , Critchley I. A., Kelly L. J. et al. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance. Antimicrob Agents Chemother. 2001. V. 45. P. 267–74.
17. Barry A. L., Fuchs P. C., Brown S. D. In vitro activities of three nonfluorinated
quinolones against representative bacterial isolates. Ibid. 1923–1927.
18. Drusano G. L., Johnson D., Rosen M. Pharmacodynamics of fluoroquinolone
antimicrobial agent in a neutropenic rat model of
Pseudomonas sepsis. Ibid. 1993. V. 37. P. 483–490.
19. Fox K. K., Knapp J. S., Holmess K. K. Antimicrobial resistance in
Neisseria gonorrhoeae in the United States, 1988–1994: the emergence
of decreased susceptibility to the fluoroquinolones. J Infect Dis 1997. V.
175. P. 1396–1403.
20. Fukuda H., Hosaka M., Iyobe S. et al. nfxC-type quinolones resistance in
a clinical isolate of Pseudomonas aeruginosa. Antimicrob Agents
Chemother 1995. V. 39. P. 790–792.
21. Goni H., Jiang Z-D., Adachi J. A. et al. In vitro antimicrobial susceptibility
testing of bacterial enteropathogens causing travelers diarrhea in four
geographic regions. Ibid. 2001. V. 45. P. 210–216.
22. Oethinger M., Kern W. V., Jellen-Ritter A. S. et al. Ineffectiveness of
topoisomerase mutations in mediating clinically significant fluoroquinolone
resistance in Esherichia coli in the absence of the acrAB efflux
pump. Ibid. 2000. V. 44. P. 10–13.
23. Une T, Fujimoto T, Sato K, Osada Y. Ibid. 1988. V. 32. P. 1336–1340.
24. Vila J., Vargas M., Ruiz J. et al. Quinolone resistance in enterotoxigenic
Esherichia coli causing diarrhea in travelers to India in comparison with
other geographical areas. Ibid. 2000. V. 44. P. 1731–1733.
25. Yoshida H., Bogahi M., Nakamura M. et al. Quinolone resistance-determining
region in the DNA gyrase gyrA gene of Esherichia coli. Ibid. 1990. V.
34. P. 1271–1272.
26. Yoshida H., Muratani T., Iyobe S. et al. Mechanisms of high-level resistance
to quinolones in urinary tract isolates of Pseudomonas aeruginosa.
Ibid. 1994. V. 38. P. 1466–1469.
27. Waites K., Rand K., Jenkins S. et al. Multicenter in vitro comparative
study of fluoroquinolones after four years of widespread clinical use.
Diagn. Microbiol Infect 1994. V. 3. P. 181–189.
28. Bonfiglo G., Cascone C., Azzarelli C. et al. Levofloxacin in vitro activity
and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates.
J Antimicrob Chemother 2000. V. 45. P. 115–117.
29. Denton M., Kerr K. G. Microbial and clinical aspects of infection associated
with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998. V. 11. P.
57–80.
30. Lecso-Bornet M., Pierre J., Sarkis-Karam P. et al. Susceptibility of
Xantomonas maltophilia to six quinolones and study of outer membrane
proteins in resistant mutants selected in vitro. Antimicrob Agents
Chemother 1992. V. 36. P. 669–671.
31. Lomovskaya O., Warren M. S., Lee A. et al. Identification and characterization
of inhibitors of multidrug resistance efflux pumps in Pseudomonas
aeruginosa. Ibid. 2001. V. 45. P. 105–106.
32. Nakano M., Deguchi I., Kawamura J. et al. Mutations in the gyrA and
parC genes in fluoroquinolone-resistant clinical isolates of Pseudomonas
aeruginosa. Ibid. 1997. V. 41. P. 2289–2291.
33. Poole K., Krebes K., Mc Nally C. et al. Multiple antibiotic resistance in
Pseudomonas aeruginosa: evidence for involvement of an efflux operon. J
Bacteriol 1993. V. 175. P. 7363–7372.
34. Renau T., Leger R., Flamme E. et al. Inhibitors of efflux pumps in
Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone
antibacterial levofloxacin. J Med Chem 1999. V. 42. P. 4928–4931.
35. Schmitz F. J., Sadurski R., Verhoef J. et al. Typing of 154 clinical isolates
of Stenotrophomonas maltophilia by pulsed field gel electrophoresis and
determination of the in vitro susceptibilities of these strains to 28 antibiotics.
J Antimicrob Chemother 2000. V. 45. P. 921–924.
36. Tornsberry C. Susceptibility of clinical bacterial isolates to ciprofloxacin
in the United States. Infection 1994. V. 22. Suppl. 2. P. 380–389.
37. Tornsberry C., Sahm D. F. Antimicrobial resistance in respiratory tract
pathogenes: results of international surveillance study. J Chemother
1999. V. 46. Suppl. 1. P. 15–23.
38. Pestova E., Millichap J., Noskin G., et al. Intracellular targets of moxifloxacin:
a comparison with other fluoroquinolones. J Antimicrob
Chemother 2000. V. 45. P. 583–590.
39. Blondean J. M., Zhoo X., Hanson G. et al. Mutant prevention concentrations
of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.
Antimicrob Agents Chemother 2001. V. 45. P. 589–592.
40. Chen D. K., Mc Geer A., De Azavedo J. C. et al. Decreased susceptibility
of Streptococcus pneumoniae to fluoroquinolones in Canada. New Engl J
Med 1999. V. 341. P. 233–239.
41. Doern G. V., Brueggemann A. B., Holley H. P. et al. Antimicrobial resistance
of Streptococcus pneumoniae recovered from outpatients in the
United States during the winter months of 1994 to 1995: results for a 30-
center national surveillance study. Antimicrob Agents Chemother 1996. V. 40. P. 1208–1213.
42. Doern G. V., Pfaller M. A., Kugler K. et al. Prevalense of antimicrobial
resistance among respiratory tract isolates of Streptococcus pneumoniae in
North America. P. 1997 results from the Sentry antimicrobial surveillance
program. Clin Infect Dis 1998. V. 27. P. 764–770.
43. Doern G. V., Brueggemann A. B., Holley H. P. et al. Antimicrobial resistance
with Streptococcus pneumoniae in the United States 1997-1998.
Emerg Infect Dis 1999. V. 5. P. 757–765.
44. Fukuda H., Hiramatsu K. Primary target of fluoroquinolones in
Streptococcus pneumoniae. Antimicrob Agents Chemother. 1999. V. 43. P.
410–412.
45. Gootz T., Zaniewski R., Haskel S. et al. Activity of the new fluoroquinolone
trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase
IV mutans of Streptococcus pneumoniae selected in vitro. Ibid.
1996. V. 40. P. 2691–697.
46. Gootz T., Zaniewski R., Haskel S. Activities of trovafloxacin compared
with those of other fluoroquinolones against purified topoisomerases and
grlA mutants of Staphylococcus aureus. Ibid. 1999. V. 43. P. 1845–1855.
47. Ho P. L., Que T., Tsang D. N-E. et al. Emergence of fluoroquinolones
resistance among multiply resistant strain of Streptococcus pneumoniae in
Hong Kong. Ibid. 1310–1313.
48. Hoellman D. B., Kelly L. M., Jacobs M. R. et al. Comparative antianaerobic
activity of BMS 284756. Ibid. 2001. V. 45. P. 589–592.
49. Ito H., Yoshida H., Bogaki-Shonai M. et al. Quinolone resistance mutations
in the DNA gyrase gyrA and gyrB genes of Staphylococcus aureus.
Ibid. 1994. V. 38. P. 2014–023.
50. Jones M. E., Sahm D. F., Martin N. et al. Prevalence of gyrA , gyrB, parC
and parE mutations in clinical isolates of Streptococcus pneumoniae with
decreased susceptibilities to different fluoroquinolones and originating
from worldwide surveillance studies during the 1997–1998 respiratory
season. Ibid. 2000. V. 44. P. 462–466.
51. Khurshid M. A., Chou T, Carey R et al. Staphylococcus aureus with
reduced susceptibility to vancomycin. Illinois,1999. VVWP 2000. V. 48. P. 1165–1167.
52. Linde M-S., Schmidt M., Fuchs E. In vitro activities of six quinolones and
mechanisms of resistance in Staphyloccocus aureus and coagulase-negative
staphyloccocus. Antimicrob Agents Chemother 2001. V. 45. P. 1553–1557.
53. Munoz-Bellido J. L., Alonso-Manzanares M. A., Yague- Guirao G. In vitro
activities of 13 fluoroquinolones against Staphyloccocus aureus isolates
with characterized mutations in gyrA, gyrB, grlA and norA and against
wild-type isolates. Ibid. 1999. V. 43. P. 966–968.
54. Sahm D. F., Karlowsky S. A., Kelly L. J. et al. Need for annual surveillance
of antimicrobial resistance in Streptococcus pneumoniae in the
United States. P. 2-year longitudinal analysis. Ibid. 2001. V. 45. P. 1037–1042.
55. Schmitz F. J., Jones M. E., Hofmann B. et al. Characterization of gyrA,
gyrB, grlA and grlB mutations in 116 unrelated isolates of Staphylococcus
aureus and effects of mutations on ciprofloxacin MIC. Ibid. 1998. V. 42. P.
1249–1252.
56. Takanata M., Yonezawa M., Natsubara N. et al. Antibacterial activity of
quinolones against coagulase-negative staphylococci and the quinolone
resistance-determining region of the gyrA genes from six species. J
Antimicrob Chemother 1997. V. 40. P. 384– 386.
57. Tanaka M., Onodera Y., Uchida K. et al. Inhibitory activities of quinolones
against DNA gyrase and topoisomerase IV purified from Staphylococcus
aureus. Antimicrob Agents Chemother 1997. V. 41. P. 2362–2366.
58. Blondean J. A review of clinical trials with fluroquinolones with an
emphasis on new agents. Expert Opin. Invest Drugs 2000. V. 59. P. 383–413.
59. King A., May J., French G. et al. Comparative in vitro activity of gemifloxacin.
J Antimicrob Chemother 2000. V. 45. P. Suppl. 1. P. 1–12.
60. Wise R., Andews J. M. The in vitro activity and tentative breakpoint of
gemifloxacin, a new fluoroquinolone. Ibid. 1999. V. 44. P. 679–688.
61. Bildenbach D. J., Jones R. N., Marshall S. A. et al. Antimicrobial activity
of gatifloxacin against Stenotrophomonas maltophilia and Burkholderia
species. Drugs 1999. V. 58. P. Suppl. 2. P. 180–181.
62. Weigel L. M., Steward C. D., Tenover F. C. gyrA mutations associated
with fluoroquinolone resistance in eight species of Enterobacteriaceae.
Antimicrob Agents Chemother 1998. V. 42. P. 2661–2667.
63. Cohn M. L., Waites K. B. Antimicrobial activities of gatifloxacin against
nosocomial isolates of Stenotrophomonas maltophilia measured by MIC
and time-kill studies. Ibid. 2001. V. 45. P. 2126–2128.
|
[ Ñîäåðæàíèå âûïóñêà N 1 | Âûïóñêè æóðíàëà | Ñïèñîê æóðíàëîâ ] |
|
|